Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).
Daniel Keizman
No relevant relationships to disclose
Maya Ish-Shalom
No relevant relationships to disclose
Jason David Taksey
No relevant relationships to disclose
Roberto Pili
No relevant relationships to disclose
Hans J. Hammers
No relevant relationships to disclose
Mario A. Eisenberger
No relevant relationships to disclose
Ben Boursi
No relevant relationships to disclose
Raanan Berger
No relevant relationships to disclose
Natalie Maimon
No relevant relationships to disclose
Maya Gottfried
No relevant relationships to disclose
Henry Hayat
No relevant relationships to disclose
Avivit Peer
No relevant relationships to disclose
Svetlana Kovel
No relevant relationships to disclose
Avishay Sella
No relevant relationships to disclose
Michael Anthony Carducci
No relevant relationships to disclose